Baseline Characteristic (N = 1905) |  | |
---|---|---|
 | Available data | Included (N = 1829) |
Socio-demographic | ||
 Age, mean (SD), years | 1905 | 82.44 (6.50) |
 Gender, Male, n(%) | 1905 | 597 (32.64) |
 School education, n(%) |  |  |
 Low level of education | 1811 | 677 (37.01) |
 Middle level of education |  | 711 (38.87) |
 High level of education |  | 357 (19.52) |
 Living arrangements n(%) |  |  |
 Living alone | 1874 | 842 (46.04) |
 Living with others |  | 959 (52.43) |
Health conditions | ||
 Hypertension n(%) | 1814 | 952 (52.05) |
 Diabetes mellitus n(%) | 1814 | 261 (14.27) |
 Atrial arrhythmia n(%) | 1811 | 278 (15.20) |
 Thrombo embolic disease n(%) | 1808 | 141 (7.71) |
 Cardiovascular disease n(%) | 1810 | 269 (14.71) |
 Congestive heart failure n(%) | 1813 | 103 (5.63) |
 Chronic respiratory disease n(%) | 1269 | 17 (0.93) |
 Renal insufficiency n(%) | 1269 | 57 (3.12) |
 Connectivitis n(%) | 1814 | 62 (3.39) |
 Prebaseline cancer n(%) | 1814 | 337 (18.43) |
Examination findings | ||
 Frailty Fried’s criteria |  |  |
 Non frail | 1886 | 936 (51.18) |
 Frail |  | 893 (48.82) |
 Cognitive: MMSE score (%) |  |  |
 No impairment ≥26 | 1851 | 961 (52.54) |
 Mild impairment 21–25 |  | 484 (26.46) |
 Moderate impairment 11–20 |  | 310 (16.95) |
 Severe impairment 0–10 |  | 27 (1.48) |
 Nutritional status |  |  |
 MNA score ≥ 24 | 1847 | 1084 (59.27) |
 MNA score 17–23.5 |  | 610 (33.35) |
 MNA score < 17 |  | 81 (4.43) |
 ADL score(/6), median (IQR) | 1899 | 6 (1) |
 IADL score(/8), median (IQR) | 1884 | 6 (4) |
Laboratory results | ||
 Hemoglobin, Mean ± SD g/dl | 1854 | 13.33 (1.41) |
 Mean corpuscular volume, median (IQR), fl | 1854 | 91 (6) |
 White blood cell count, median (IQR), 10^3/cm | 1854 | 6.63 (2.38) |
 Platelets, median (IQR), 10^3/cm | 1832 | 231 (80) |
 Anemia n(%) | 1832 | 381 (20.83) |
 C-reactive protein, median (IQR), mg/L | 1861 | 2.1 (3.9) |
Renal function: CKD-EPI MD | ||
 Normal (eGFR ≥90 ml/min/1.73m2), n(%) | 1875 | 162 (8.86) |
 Mild decrease (eGFR 60–89 ml/min/1.73m2), n(%) |  | 1120 (61.24) |
 Moderate to severe decrease (eGFR 30–59 ml/min/1.73m2), n(%) |  | 484 (26.46) |
 Severe decrease (eGFR≤29 ml/min/1.73m2), n(%) |  | 43 (2.35) |